Analyse Sionna Therapeutics, Inc. (SION) — Kairos Score 46/100

À propos de Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

8 transactions — 0 achats et 2 ventes déclarés par les dirigeants de Sionna Therapeutics, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur SION dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur SION.

• Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?
• FDA clears first generic radioligand drug; Sionna turns to layoffs

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.